Outcomes of COVID-19 in heart failure, LVAD, and heart transplant patients in an advanced heart failure practice

George, Susan R.; Cunningham, Luke; Nelson, David P.; Horstmanshof, Douglas; Long, James W.; Banayosy, A.M. El

doi:10.1016/j.ahjo.2022.100223

Cited by 1 publication

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Heart Failure and Myocarditismentioning

confidence: 99%

“…While the authors highlight that most patients, including OHT (86.5%) and HF (69.8%) patients were on therapeutic anticoagulation, all LVAD patients were therapeutically anticoagulated and possibly conferred some benefit from this. 103 A few cases are available in the literature of LVAD pump thrombosis in the setting of COVID-19. 102,104,105 Acute heart failure has also been described in COVID-19, dating back to the first cases in the United States from Washington state, where a third of patients developed acute cardiomyopathy within a cohort with an exceptionally high mortality rate of 67%.…”

Section: Heart Failure and Myocarditismentioning

confidence: 99%

See 1 more Smart Citation

Interaction of COVID-19 With Common Cardiovascular Disorders

Boulos

Freeman

Henry

et al. 2023

Circulation Research

View full text Add to dashboard Cite

The onset and widespread dissemination of the severe acute respiratory syndrome coronavirus-2 in late 2019 impacted the world in a way not seen since the 1918 H1N1 pandemic, colloquially known as the Spanish Flu. Much like the Spanish Flu, which was observed to disproportionately impact young adults, it became clear in the early days of the coronavirus disease 2019 (COVID-19) pandemic that certain groups appeared to be at higher risk for severe illness once infected. One such group that immediately came to the forefront and garnered international attention was patients with preexisting cardiovascular disease. Here, we examine the available literature describing the interaction of COVID-19 with a myriad of cardiovascular conditions and diseases, paying particular attention to patients diagnosed with arrythmias, heart failure, and coronary artery disease. We further discuss the association of acute COVID-19 with de novo cardiovascular disease, including myocardial infarction due to coronary thrombosis, myocarditis, and new onset arrhythmias. We will evaluate various biochemical theories to explain these findings, including possible mechanisms of direct myocardial injury caused by the severe acute respiratory syndrome coronavirus-2 virus at the cellular level. Finally, we will discuss the strategies employed by numerous groups and governing bodies within the cardiovascular disease community to address the unprecedented challenges posed to the care of our most vulnerable patients, including heart transplant recipients, end-stage heart failure patients, and patients suffering from acute coronary syndromes, during the early days and height of the COVID-19 pandemic.

show abstract